Our findings indicate that myocardial damage in patients with diabetes affects diastolic function before systolic function. The intentional assessment of diastolic function is advisable for early detection of LV dysfunction before clinical symptoms appear, with follow-up to detect further deterioration of cardiac status.
One hundred and fifty-seven young cardiac asymptomatic type 1 diabetics
and 54 control subjects were examined with M-mode echocardiography to
elucidate the early changes in left ventricular systolic function (LVSF) in diabetes
mellitus. Out of 157 diabetics a group of 40 newly diagnosed diabetics
without diabetic complications was formed (retinopathy, nephropathy, autonomic
neuropathy). They had ejection fraction (71.3 ± 3.3%), fractional
shortening (FS = 40.5 ± 2.3%) and corrected mean velocity of circumferential
fiber shortening (1.23 ± 0.11 circ/s) significantly higher than those of the control
subjects (65.7 ± 3.0, 36.3 ± 2.3, 1.08 ± 0.09), but end-diastolic volume
index (as preload, 72.9 ± 11.7 ml/m2), end-systolic meridional wall stress
(MWSs, as afterload, 65.7 ± 12.4kdyn/cm2) and heart rate (HR = 72.8 ±
10.0 bpm) were unchanged significantly compared to the control values (68.6
± 10.8, 70.9 ± 15.0, 74.4 ± 11.0). In 90% of the newly diagnosed diabetics
the FS was above the 95% confidence limits of the control FS/MWSs relation,
on the background of a significant difference (p < 0.001) in the frequency
distribution between diabetics and control group (37%). These changes were
probably due to increased myocardial contractility, rather than the changes in
the loading condition since the other determinants of LVSF, such as preload,
afterload and HR, were unchanged. In conclusion, our data impose the
hypothesis that one of the early manifestations of the noncoronary diabetic
cardiopathy is the increased myocardial contractility.
The present study was designed as an attempt to elucidate some reasons for
the contradictory findings concerning the relationship between the duration of
diabetes and left ventricular (LV) function. 157 young (age 26.2 years) cardiacasymptomatic
type 1 diabetics were divided into the following five groups:
(1) without complications (n = 86); (2) with mild complications (n = 39);
(3) with severe complications (n = 32); (4) with microangiopathy (MIC) - retinopathy
and/or nephropathy only (n = 39), and (5) with cardiac autonomic
neuropathy (CAN) only (n = 22). LV function was studied by M-mode echocardiography.
Fractional shortening (FS), isovolumic relaxation time (IRT)
and interval from minimal LV dimension to mitral valve opening (MD-MO)
correlated with the duration of disease in the entire group (r = -0.62, r = 0.71,
r = 0.72, p < 0.0001, n = 157), and in the complications free group (r = -0.54,
r = 0.49, r = 0.49, p < 0.001, n = 86). These relations were weaker (r < 0.05) in
the milder group (FS: r = -0.34, p < 0.03; IRT: r = 0.41, p < 0.04) and were
statistically not significant (p > 0.05) in the severe group (FS: r = 0.06; IRT: r =
-0.10), MIC group (FS: r = -0.25; MD-MO: r = 0.40) and CAN group (FS: r =
-0.18; MD-MO: r = 0.22). Based on the lines of best fit for the groups, we
found that in early years of diabetes even for similar duration, the patients
with complications (mild, severe, MIC or CAN) had more (p < 0.05) prolonged
IRT and lower FS than those without complications.
The findings presented show that the specific diabetic complications (MIC
and CAN) affect the relationship between the duration of diabetes and LV
function, and accelerate the appearance of LV dysfunction. This fact may
explain the contradictory findings concerning the influence of the duration of
disease on LV function.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.